SuperworthAstera Labs ALAB
- Market cap
- $44.6B
- PE
- 127×
- 1y median 173×
- Forward PE
- 45.4×
- 3y median 67.5×
- Price to sales
- 37.1×
- EV/EBIT
- 159×
- Revenue, 12 months
- $1.2B
- +98% on a year ago
- Net margin
- 30.7%
- Free cash flow yield
- 0.6%
Astera Labs trades at 127× trailing earnings, cheaper than 87% of the last ten years. Revenue was $1.2B over the last twelve months, up 98% on a year earlier with a 31% net margin.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $36.9M | $50.5M | $65.3M+269% | $76.8M+619% | $113.1M+206% | $141.1M+179% | $159.4M+144% | $191.9M+150% | $230.6M+104% | $270.6M+92% | $308.4M+93% | $392.4M+105% | |
| Cost of revenue | $8.8M | $11.5M | $14.7M+10% | $17M+656% | $25.2M+186% | $36.6M+219% | $40M+172% | $46.4M+173% | $54.8M+117% | $66.1M+80% | $73.2M+83% | $104.8M+126% |
| Gross profit | $28.1M | $39M | $50.5M+1087% | $59.9M+609% | $87.9M+213% | $104.4M+168% | $119.4M+136% | $145.6M+143% | $175.8M+100% | $204.5M+96% | $235.1M+97% | $287.6M+98% |
| R&D | $20.6M | $19.7M | $53.6M+251% | $40.1M+125% | $50.7M+146% | $56.5M+188% | $64.6M+21% | $66.7M+66% | $78.9M+56% | $93.8M+66% | $125.6M+95% | $135.9M+104% |
| SG&A | $9.5M | $10.4M | $79.9M+910% | $44.1M+439% | $46.1M+388% | $47.8M+362% | $43.6M−46% | $39.1M−11% | $41.5M−10% | $43.7M−9% | $47.7M+9% | $62.4M+60% |
| −$2M | $9M | −$83M+338% | −$24.3M+38% | −$8.9M+350% | $144K−98% | $11.3M | $39.8M | $55.4M | $67M+46399% | $61.8M+448% | $89.2M+124% | |
| Pre-tax income | −$253K | $10.7M | −$80.4M+364% | −$14.1M−12% | $2M | $10.7M+0% | $21.7M | $50.7M | $66.9M+3217% | $78.9M+637% | $73.4M+238% | $102.8M+103% |
| $2.9M | −$3.6M | $12.6M+10129% | −$6.5M | $9.6M+235% | −$14M+286% | −$10.1M | −$560K−91% | −$24.3M | $33.9M | −$6.9M−32% | −$50.3M+8876% | |
| Net income | −$3.1M | $14.3M | −$93M+433% | −$7.5M−62% | −$7.6M+143% | $24.7M+73% | $31.8M | $51.2M | $91.1M | $45M+82% | $80.3M+152% | $153.1M+199% |
| −$0.08 | $0.37 | −$1.77+261% | −$0.05−91% | −$0.05−38% | $0.15−60% | $0.18 | $0.29 | $0.50 | $0.25+67% | $0.44+144% | $0.83+186% | |
| 37.5M | 38.6M | 52.5M+47% | 155.2M+324% | 156.8M+319% | 159.9M+314% | 178.1M+239% | 178.1M+15% | 180.6M+15% | 181.3M+13% | 181.2M+2% | 183.3M+3% |
EPS, diluted: 3 periods, Q4 FY23 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: 3 periods, Q4 FY23 to Q4 FY25: share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Estimates
Next earnings report: .
| Quarter | Revenue | Range | EPS | Range | Analysts |
|---|---|---|---|---|---|
| Q3 FY26 | $550.8M | $550.4M to $552.5M | $1.19 | $1.18 to $1.20 | 14 |
| Q4 FY26 | $656.3M | $629.7M to $678.9M | $1.42 | $1.34 to $1.47 | 14 |
| Q1 FY27 | $699.2M | $660.1M to $755.4M | $1.48 | $1.38 to $1.64 | 8 |
| Q2 FY27 | $742M | $700.5M to $801.7M | $1.57 | $1.45 to $1.73 | 6 |
| Q3 FY27 | $780.1M | $736.5M to $842.8M | $1.65 | $1.53 to $1.83 | 6 |
| Q4 FY27 | $848M | $800.5M to $916.1M | $1.79 | $1.66 to $1.98 | 12 |
| Q1 FY28 | $799.6M | $754.8M to $863.9M | $1.78 | $1.65 to $1.96 | 13 |
| Q2 FY28 | $834.8M | $788.1M to $901.9M | $1.84 | $1.71 to $2.04 | 7 |
Peers
Companies in Semiconductors nearest Astera Labs' size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| ALABAstera Labs | $44.6B | 127× | 173× | 45.4× | 37.1× | +98% | 30.7% |
| TERTeradyne | $48.3B | 42.4× | 28.4× | 31.3× | 10.8× | +58% | 25.8% |
| MCHPMicrochip Technology | $40.2B | 111× | 58.2× | 18.8× | 7.8× | +21% | 9.3% |
| MPWRMonolithic Power Systems | $56B | 69.8× | 74.4× | 35.1× | 17.1× | +29% | 24.5% |
| NXPINXP Semiconductors | $59.2B | 20.0× | 22.5× | 14.1× | 4.5× | +9% | 22.6% |
| TELTE Connectivity | $60.2B | 20.4× | 19.1× | 16.5× | 3.1× | +17% | 15.6% |
| ONON Semiconductor | $28.1B | 46.3× | 23.4× | 18.7× | 4.5× | −3% | 10.2% |
| CRDOCredo Technology | $27.7B | 52.4× | 110× | 20.2× | 17.4× | +165% | 33.8% |
| QQnity Electronics | $23B | 39.4× | 45.0× | 22.5× | 4.4× | +15% | 11.2% |
| ENTGEntegris | $20.6B | 67.6× | 42.9× | 30.0× | 6.2× | +3% | 9.2% |
| MTSIMACOM Technology Solutions | $18B | 75.5× | 83.2× | 28.6× | 15.5× | +28% | 20.7% |
| Peer median | $34.2B | 49.4× | 44.0× | 21.4× | 7.0× | +19% | 18.2% |
Investors who own it
Investors we follow who held Astera Labs at the end of Jun 30, 2026, from their 13F filings.
- Gavin BakerAtreides Management5.3% of portfoliotrimmed
- Lee AinslieMaverick Capital4.7% of portfolioadded
- Baillie GiffordBaillie Gifford0.1% of portfoliotrimmed
More on Astera Labs
Each number over time
- PE ratio
- Forward PE
- Price to sales ratio
- Price to free cash flow
- Price to book ratio
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Where it ranks
- #6of 433Technology stocks with the fastest revenue growth
- #3of 213Technology stocks with the fastest earnings growth
- #1of 37Semiconductor stocks with the fastest earnings growth
- #3of 97Technology stocks with the fastest expected revenue growth
- #3of 74Semiconductor stocks with the fastest revenue growth
- #1of 23Semiconductor stocks with the fastest expected revenue growth
- #9of 75Semiconductor stocks with the highest profit margins
Its groups
About
- Industry
- Semiconductors
- Sector
- Technology
Valuation data, not investment advice. Prices as of .